

Central Lancashire Online Knowledge (CLOK)

| | |
|----------|---|
| Title | Raman spectroscopic techniques to detect ovarian cancer biomarkers in blood plasma |
| Type | Article |
| URL | https://clock.uclan.ac.uk/23949/ |
| DOI | https://doi.org/10.1016/j.talanta.2018.06.084 |
| Date | 2018 |
| Citation | Paraskevaidi, Maria, Ashton, Katherine M, Stringfellow, Helen F, Wood, Nicholas J, Keating, Patrick J, Rowbottom, Anthony W, Martin-Hirsch, Pierre L and Martin, Francis L (2018) Raman spectroscopic techniques to detect ovarian cancer biomarkers in blood plasma. <i>Talanta</i> , 189. pp. 281-288. ISSN 0039-9140 |
| Creators | Paraskevaidi, Maria, Ashton, Katherine M, Stringfellow, Helen F, Wood, Nicholas J, Keating, Patrick J, Rowbottom, Anthony W, Martin-Hirsch, Pierre L and Martin, Francis L |

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1016/j.talanta.2018.06.084>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

1 **Raman spectroscopic techniques to detect ovarian cancer biomarkers in blood plasma**

2
3 Maria Paraskevasidi^{a,1}, Katherine M. Ashton^b, Helen F. Stringfellow^b, Nicholas Wood^c, Patrick
4 Keating^c, Anthony Rowbottom^d, Pierre L. Martin-Hirsch^c and Francis L. Martin^{a,1}

5 ^a*School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1*
6 ²*HE, UK*

7 ^b*Pathology Department, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2*
8 ⁹*HT, UK*

9 ^c*Department of Obstetrics and Gynaecology, Lancashire Teaching Hospitals NHS Foundation*
10 ^{Trust, Preston PR2 9HT, UK}

11 ^d*Immunology Laboratory, Pathology Department, Lancashire Teaching Hospitals NHS*
12 ^{Foundation Trust, Preston PR2 9HT, UK}

13
14
15
16
17
18
19
20
21 ¹To whom correspondence should be addressed. Email: mparaskevasidi@uclan.ac.uk or
22 flmartin@uclan.ac.uk Tel: +44 (0) 1772 89 6482

25 **Table S1:** Detailed patient information. OC: ovarian cancer; FIGO: International Federation of
 26 Gynecology and Obstetrics; diff: differentiated; mod: moderately;

| Participant Number | Diagnosis/stage | Class for spectroscopy | Age | CA-125 level |
|--------------------|---|------------------------|-----|--------------|
| 1 | Serous borderline FIGO stage 1C | Early OC | 77 | 348 |
| 2 | Clear cell adenocarcinoma FIGO stage 1C | Early OC | 69 | 32 |
| 3 | G3 mixed endometrioid & clear cell adenocarcinoma FIGO stage 1C | Early OC | 74 | 43 |
| 4 | High grade serous adenocarcinoma FIGO stage 1c | Early OC | 82 | 192 |
| 5 | G1 endometrioid adenocarcinoma, stage 1 | Early OC | 88 | 1142 |
| 6 | High grade serous adenocarcinoma FIGO stage 3b | Late OC | 69 | 83 |
| 7 | High grade serous adenocarcinoma FIGO stage 3b | Late OC | 62 | 132 |
| 8 | High grade serous adenocarcinoma FIGO stage 3c | Late OC | 72 | 642 |
| 9 | High grade serous adenocarcinoma, stage 1 | Early OC | 77 | 135 |
| 10 | G3 endometrioid/serous adenocarcinoma FIGO stage 1c | Early OC | 73 | 3165 |
| 11 | Well diff mixed type adenocarcinoma FIGO stage 1a | Early OC | 48 | 93 |
| 12 | Serous adenocarcinoma FIGO stage 1C | Early OC | 58 | 185 |
| 13 | Borderline mucinous tumour FIGO stage 1C2 | Early OC | 59 | 67 |
| 14 | High grade serous adenocarcinoma FIGO stage 3c | Late OC | 85 | 483 |
| 15 | Borderline mucinous tumour FIGO stage 1A | Early OC | 79 | 21 |

| | | | | |
|----|---|----------|----|------|
| 16 | G3 clear cell/endometrioid adenocarcinoma FIGO stage 1C2 | Early OC | 73 | 840 |
| 17 | High grade serous carcinoma FIGO stage 3a2 | Late OC | 67 | 800 |
| 18 | High grade serous carcinoma, minor endometrioid & clear cell adenocarcinoma FIGO stage 3C | Late OC | 56 | 1000 |
| 19 | Mixed endometrioid adenocarcinoma & dediff carcinoma G3 FIGO stage 2A | Late OC | 78 | 319 |
| 20 | High grade serous adenocarcinoma FIGO stage 1C2 | Early OC | 59 | 8 |
| 21 | High grade serous adenocarcinoma FIGO stage 3C | Late OC | 65 | 187 |
| 22 | Poorly diff mucinous adenocarcinoma, stage 1 | Early OC | 60 | 86 |
| 23 | Mod to poorlu diff metastatic adenocarcinoma. Stage 3 | Late OC | 67 | 9 |
| 24 | Well diff mucinous adenocarcinoma FIGO stage 1A | Early OC | 51 | 25 |
| 25 | Granulosa cell tumour FIGO stage 1C2 | Early OC | 87 | 360 |
| 26 | High grade mixed serous & clear cell adenocarcinoma FIGO stage 3A2 | Late OC | 60 | 39 |
| 27 | Clear cell cancer of ovary, stage 1A | Early OC | 54 | 23 |
| 28 | Adenomyosis/prolapse | Control | 81 | 13 |
| 29 | Leiomyoma/prolapse | Control | 72 | 20 |
| 30 | Normal/heavy periods | Control | 40 | 12 |
| 31 | Heavy periods | Control | 39 | 18 |
| 32 | Leiomyoma/abnormal smear | Control | 60 | 24 |
| 33 | Leiomyoma/fibroids | Control | 62 | 18 |
| 34 | Benign mucinous cystadenoma | Control | 60 | 23 |
| 35 | Normal/prolapse | Control | 55 | 8 |
| 36 | Adenomyosis/heavy periods | Control | 46 | 18 |
| 37 | Polyp/prolapse | Control | 48 | 11 |

| | | | | |
|----|--|---------|----|-----|
| 38 | Normal/prolapse | Control | 78 | 6 |
| 39 | Complex hyperplasia/post-menopausal bleeding | Control | 56 | 12 |
| 40 | Leiomyoma/heavy periods | Control | 45 | 16 |
| 41 | Leiomyoma/heavy periods | Control | 54 | 7 |
| 42 | Leiomyoma/heavy periods | Control | 45 | 58 |
| 43 | Leiomyoma/heavy periods | Control | 47 | 21 |
| 44 | Benign teratoma of ovary | Control | 45 | 87 |
| 45 | Simple hyperplasia/irregular bleeding | Control | 53 | 17 |
| 46 | Normal/prolapse | Control | 80 | 16 |
| 47 | Leiomyoma/prolapse | Control | 63 | 29 |
| 48 | BRCA1 mutation | Control | 44 | 32 |
| 49 | Leiomyoma/fibroids | Control | 55 | 143 |
| 50 | Normal/prolapse | Control | 48 | 17 |
| 51 | Benign simple ovarian cyst | Control | 57 | 26 |
| 52 | Normal/prolapse | Control | 68 | 9 |
| 53 | Leiomyoma | Control | 82 | 481 |
| 54 | Leiomyoma | Control | 40 | 7 |
| 55 | Normal/heavy periods | Control | 48 | 27 |

27

28

29

30

31

32

33




Figure S1: Diagnostic segregation between ovarian cancer (OC) patients and healthy controls according to their age (OC ≥ 60 years ($n=20$); Control ≥ 60 years ($n=10$); OC <60 years ($n=7$); Control <60 years ($n=19$)). Sensitivity and specificity are provided for (A) individuals older than 60 years old and (B) individuals younger than 60 years old after Raman analysis.